Fewer pills, more flexibility in dosing: Roche ’s new Esbriet tablet formulation approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF)

Roche today announced that the European Commission (EC) has approved a new tablet formulation of Esbriet ® (pirfenidone) for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF), a fatal condition that causes irreversible, progressive scarring of the lungs.

Source: Roche Investor Update - June 27, 2017 Category: Pharmaceuticals Source Type: news